AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — FY2017 Earnings Presentation

38 slides from AMAG Pharmaceuticals's earnings presentation, Feb 27, 2018

  1. Slide 1: AMAG Pharmaceuticals 2017 Financial Results

    AMAG Pharmaceuticals 2017 Financial Results February 27, 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, be

  3. Slide 3: Today's Agenda

    Today’s Agenda 3 2017 Highlights and Recent Events1 4 Key Priorities and Closing Remarks 3 2017 Financial Overview 5 Q&A 2 Product Portfolio Update

  4. Slide 4: 2017 Highlights and Recent Events

    2017 Highlights and Recent Events

  5. Slide 5: Solid Execution

    Solid Execution Intrarosa  Launched Intrarosa; drove broad awareness and access  Phase 3 hypoactive sexual desire disorder (HSDD) study initiated by partner, Endoceutics Bremelanotide  Completed clinical work with partner, Palatin, for planned NDA submission in Q1-2018  Launched HCP condition aw

  6. Slide 6: Solid Execution

    Solid Execution Intrarosa  Launched Intrarosa; drove broad awareness and access  Phase 3 hypoactive sexual desire disorder (HSDD) study initiated by partner, Endoceutics Bremelanotide  Completed clinical work with partner, Palatin, for planned NDA submission in Q1-2018  Launched HCP condition aw

  7. Slide 7: Strong 2017 Product Revenue Growth

    Strong 2017 Product Revenue Growth1 ($M) 2016 2017 $531.8 $609.8 GAAP Product Revenue  14.7% 7 2016 2017 $548.8 $615.3 Non-GAAP Product Revenue2,3  12.1% Makena revenue CBR revenueFeraheme/MuGard revenue Intrarosa revenue 1 Excludes “License fee, collaboration and other revenues” of $317,000 in 20

  8. Slide 8: Product portfolio: maternal and women's health, hematology/oncology

     Treatment of iron deficiency anemia (IDA) in all eligible adult patients  The only FDA-approved therapy to reduce recurrent preterm birth in certain at-risk women  World’s largest umbilical cord stem cell collection and storage company  Candidate for the treatment of severe preeclampsia  An in

  9. Slide 9: Product Portfolio Update

    Product Portfolio Update •Feraheme® • Makena® • Cord Blood Registry® • Intrarosa® 9

  10. Slide 10: Feraheme is the only IV iron demonstrating effective treatment for IDA

    FERAHEME® is the only IV iron demonstrating effective treatment for IDA in adult patients with 1g of iron across 2 fifteen-minute infusions 3-8 days apart 10 Feraheme Broad IDA Label1 Approved February 2, 2018 Strong Data in New Broad IDA Feraheme Label… I V I R O N D E F I C I E N C Y A N E M I A :

  11. Slide 11: Improvements in Fatigue-Related Symptoms with Feraheme

    Improvements in Fatigue-Related Symptoms with Feraheme 11 I V I R O N D E F I C I E N C Y A N E M I A : F E R A H E M E * FACIT: Functional Assessment of Chronic Illness Therapy 1 Vadhan-Raj S, et al. Am J Hematol. 2014;89:7–12. 2 Strauss et al. J Commun Support Oncol.2016;14 (8):342-350. Change fro

  12. Slide 12: Lower Incidence of Severe Hypophosphatemia with Feraheme

    12 Lower Incidence of Severe Hypophosphatemia with Feraheme1 Hypophosphatemia can have important clinical implications2 – Acutely: muscle weakness and pain, fatigue – Chronically: osteomalacia (impaired bone mineralization), bone pain, fractures, muscle weakness I V I R O N D E F I C I E N C Y A N E

  13. Slide 13: Large Market Opportunity with New Broad Label

    Large Market Opportunity with New Broad Label Feraheme 12% Injectafer 29% Other IV irons 59% 13 I V I R O N D E F I C I E N C Y A N E M I A : F E R A H E M E Q4-2017 U.S. Non-dialysis IV Iron Market1 1 AMAG estimates current market using IQVIA data and internal analytics.

  14. Slide 14: Launch Strategy and Growth Drivers

    Launch Strategy and Growth Drivers 14 Expand Access  New contract opportunities with key accounts and GPOs Expand Customer Patient Types  Hematology/Oncology  Gastrointestinal disorders  Gynecological disorders Reinforce and Enhance Differentiation  Effectively communicate 1-2-3 value propositi

  15. Slide 15: Product Portfolio Update

    Product Portfolio Update • Feraheme® •Makena® • Cord Blood Registry® • Intrarosa® 15

  16. Slide 16: Makena SC Auto-injector Approved February 14, 2018

    Efficient Discreet Administration friendly 16 Makena SC Auto-injector Approved February 14, 2018 M A T E R N A L H E A L T H : M A K E N A    Subcutaneous injection Intramuscular injection

  17. Slide 17: SC Attributes Important to Patients

    17 SC Attributes Important to Patients 1% 2% 10% 25% 28% 34% 0% 5% 10% 15% 20% 25% 30% 35% 40% Site of injection Needle thickness Route of administration Needle visibility Needle length Time for administration Relative Importance Statistically significant impact on overall preference M A T E R N A L

  18. Slide 18: Makena SC Auto-injector Expected to be Used in Majority of Treated Patients

    18 Makena SC Auto-injector Expected to be Used in Majority of Treated Patients Assuming Price Parity1 M A T E R N A L H E A L T H : M A K E N A 6% 2% 2% 8% 83% Future Prescribing3 (MDs, n=20) Current Prescribing2 (HCPs, n=30) 8% 18% 67% N/A N/A Makena SC4 Makena IM Generic HPC single-dose vial4 Comp

  19. Slide 19: Ensure SC Auto-injector Becomes the New Standard of Care

    19 Ensure SC Auto-injector Becomes the New Standard of Care M A T E R N A L H E A L T H : M A K E N A Expand use through alternative treatment sites (i.e. retail pharmacies) Rapid and easy dispensing of SC auto-injector Key Imperatives Key Tactics Manage access (price, patient out-of-pocket, reimbur

  20. Slide 20: Product Portfolio Update

    Product Portfolio Update • Feraheme® • Makena® •Cord Blood Registry® • Intrarosa® 20

  21. Slide 21: Cord Blood Registry Returned to Growth

    Returned to Growth 21 14,767 15,379 Q4-2016 Q4-2017 W O M E N ’ S H E A L T H : C O R D B L O O D R E G I S T R Y Growth in First New EnrollmentsStrong commercial execution driving new enrollments 2/3 of revenue driven by growing, recurring annual storage fees

  22. Slide 22: Product Portfolio Update

    Product Portfolio Update • Feraheme® • Makena® • Cord Blood Registry® •Intrarosa® 22

  23. Slide 23: Intrarosa is Differentiated

    Non-estrogen treatment2 Unique safety profile (no boxed warning) Differentiated MOA 23 Intrarosa is Differientiated1 W O M E N ’ S H E A L T H : I N T R A R O S A    1 Market research sponsored by AMAG and conducted by Roscow Market Research. 2 Intrarosa is converted by enzymes in the body into a

  24. Slide 24: Dyspareunia: 90% of Affected Women Not on Rx Therapy

    24 Dyspareunia: 90% of Affected Women Not on Rx Therapy W O M E N ’ S H E A L T H : I N T R A R O S A 20M women in U.S. suffer from dyspareunia, a symptom of VVA1 +18 Million2 U.S. women with dyspareunia not on prescription therapy ~1.7 Million2 U.S. women with dyspareunia treated with prescription

  25. Slide 25: Activating 18M Untreated Women: 2018 Consumer Campaign

    Activating 18M1 Untreated Women: AMAG’s 2018 Consumer Campaign W O M E N ’ S H E A L T H : I N T R A R O S A 25 Seek treatment options Consult MD Office visit or on-line Condition awareness On-line search 74,000 searches for dyspareunia per month via Google Dyspareunia is NOT a symptom of getting ol

  26. Slide 26: Key Intrarosa Growth Drivers

    26 Key Intrarosa Growth Drivers Launch Priority 1 Launch Priority 2 Launch Priority 3 Create affordable access for all patients Increase market awareness Increase HCP prescribing Launch Priority 4 Launch Priority 5 Make Intrarosa the 1st choice treatment among HCPs Educate potential patients about c

  27. Slide 27: Financial Overview

    Financial Overview 27

  28. Slide 28: Strong Financial Results While Investing in the Future: GAAP

    $151.61 $158.3 1 $14.6 ($7.1) $531.81 $609.81 $78.9 ($293.3) Q4-2016 Q4-2017 4.4% FY 2016 FY 2017 14.7% 3-months Ended December 31 12-months Ended December 31 1 Excludes “License fee, collaboration and other revenues” of $4,000 in Q4-2016, $70,000 in Q4-2017, $317,000 in 2016, and $124,000 in 2017

  29. Slide 29: Strong Financial Results While Investing in the Future: Non-GAAP

    $153.02 $159.62 $77.4 $65.7 Strong Financial Results While Investing in the Future $548.82 $230.1 $615.32 $265.7 FY 2016 FY 2017 12.1% Q4-2016 Q4-2017 4.3% 1 See slide 34 for a reconciliation of GAAP to non-GAAP financials. 2 Excludes “License fee, collaboration and other revenues” of $4,000 in Q4

  30. Slide 30: Strong Liquidity Profile

    Strong Liquidity Profile ($M) 12/31/17 12/31/16 Cash, cash equivalents and investments $329 $ 579 Principal debt outstanding Convertible senior notes (2.5%) due 2019 $ 21 $ 200 Convertible senior notes (3.25%) due 2022 320 -- Term loan facility (4.75%) due 2021 (repaid in May 2017) -- 328 Senior not

  31. Slide 31: 2018 Financial Guidance

    2018 Financial Guidance1 ($M) Total revenue $500 - $560 GAAP operating loss ($147) – ($117) Non-GAAP adjusted EBITDA $100 - $130 1 See slide 35 for a reconciliation of 2018 GAAP to non-GAAP financial guidance. 31

  32. Slide 32: 2018 Key Priorities

    2018 Key Priorities Intrarosa  Continue to drive awareness and HCP prescribing Feraheme  Launch broad IDA label and grow market share Makena  Launch subcutaneous auto-injector and drive conversion Cord Blood Registry  Continue to grow new first-time enrollments Business Development  Build share

  33. Slide 33: AMAG Pharmaceuticals Q&A

    AMAG Pharmaceuticals Q&A February 27, 2018

  34. Slide 34: Appendix

    Appendix

  35. Slide 35: Reconciliation of GAAP to Non-GAAP 2017 Financial Results

    Reconciliation of GAAP to Non-GAAP 2017 Financial Results 35 ($M) GAAP operating income (loss) Purchase accounting adjustments related to CBR deferred revenue Depreciation and intangible asset amortization Non-cash inventory step-up adjustments Stock-based compensation Adjustments to contingent cons

  36. Slide 36: Reconciliation of GAAP to Non-GAAP 2018 Financial Guidance

    Reconciliation of GAAP to Non-GAAP 2018 Financial Guidance 36 ($M) 2018 Financial Guidance Operating loss ($147) – ($117) Depreciation & intangible asset amortization 200 Stock-based compensation 23 Non-cash inventory step up and adjustments to contingent consideration 4 Acquired IPR&D 20 Non-GAAP a

  37. Slide 37: Share Count Reconciliation

    Share Count Reconciliation 37 (M) Weighted average basic shares outstanding Employee equity incentive awards GAAP diluted shares outstanding Employee equity incentive awards Non-GAAP diluted shares outstanding 4Q-2017 4Q-2016 34.8 34.3 0.1 --1 34.9 34.3 -- 0.8 34.9 35.1 2017 2016 34.9 34.3 --1 --1 3

  38. Slide 38: AMAG Pharmaceuticals 2017 Financial Results

    AMAG Pharmaceuticals 2017 Financial Results February 27, 2018

Amag Pharmaceuticals — FY2017 Earnings Presentation on 6ix